Vascepa's Key Drug Interactions Beyond Statins
Vascepa (icosapent ethyl), an EPA-only omega-3 fatty acid, primarily affects clotting factors and CYP enzymes, leading to interactions that increase bleeding risk or alter drug levels. These occur mainly with anticoagulants, antiplatelets, and CYP2C8/CYP3A4 substrates—not just statins like atorvastatin, where it boosts exposure via OATP1B1/1B3 inhibition.[1][2]
Which Anticoagulants Raise Bleeding Risk?
Vascepa inhibits platelet aggregation and prolongs bleeding time, amplifying effects of:
- Warfarin: Increases INR, requiring closer monitoring and dose adjustments.
- Direct oral anticoagulants (DOACs) like apixaban, rivaroxaban: Heightens major bleeding risk by 20-50% in combo use, per observational data.
Avoid or use lowest effective doses; monitor for bruising or bleeding.[1][3]
Antiplatelets and Aspirin Combinations
Pairs dangerously with:
- Clopidogrel or aspirin: Doubles bleeding events in trials (e.g., REDUCE-IT subgroup data showed higher GI bleeds).
- Ticagrelor or prasugrel: Similar platelet inhibition overlap raises hemorrhage odds.
Patients on dual antiplatelet therapy post-stent need hematocrit/bleeding checks every 3-6 months.[2][4]
CYP Enzyme Interactions
Vascepa weakly inhibits CYP2C8 (moderate) and CYP3A4 (weak), affecting:
- Repaglinide or pioglitazone (CYP2C8 substrates): Raises levels 20-40%, risking hypoglycemia or edema.
- Cyclosporine, tacrolimus (CYP3A4): Potential 10-20% exposure increase; monitor trough levels.
No strong induction effects noted.[1][5]
Other Common Medications to Watch
- Fibrates (e.g., gemfibrozil): Myopathy risk via separate pathways; avoid combo.
- Oral contraceptives or hormone therapy: Theoretical clotting modulation, but limited data—monitor for thrombosis.
- NSAIDs (ibuprofen): Additive GI bleed risk.
No major interactions with beta-blockers, ACE inhibitors, or metformin.[3][6]
What Happens If You Ignore These?
Concurrent use without monitoring leads to 2-3x higher bleed rates (e.g., 4.5% vs. 1.5% annual incidence). FDA label mandates warnings; consult prescriber for alternatives like low-dose omega-3s.[1][4]
Sources
[1]: FDA Vascepa Label
[2]: Drugs.com Vascepa Interactions
[3]: Medscape Vascepa Dosing
[4]: REDUCE-IT Trial (NEJM 2019)
[5]: DrugPatentWatch.com Vascepa Profile
[6]: Lexicomp Interaction Checker